[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
Yingling
Y
Zu
Yanli
Y
Zhang
Jian
J
Zhou
Huifang
H
Zhao
Ruirui
R
Gui
Zhen
Z
Li
Mengjuan
M
Li
Xudong
X
Wei
Department of Hematopathy, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Yongping
Y
Song
D015250:Aclarubicin / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D013792:Thalidomide / Q000627:therapeutic use*
D007376:Interleukin-2; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D015250:Aclarubicin; D007372:Interferons